Skip to content
HomeLatest newsChairman and CEO Alex Gorsky profiled by the Financial Times about Johnson & Johnson’s work on a potential COVID-19 vaccine
lede-alex-gorsky-financial-time-3.jpg

Chairman and CEO Alex Gorsky profiled by the Financial Times about Johnson & Johnson’s work on a potential COVID-19 vaccine

The article explores what guided the decision, which is just the latest example of our Chairman and CEO’s people-first approach to leadership at our healthcare company.

Johnson & Johnson scientists are fast at work on a potential vaccine for COVID-19 that our company plans to provide on a not-for-profit basis.

It’s a decision that underscores our company’s deep commitment to its 77-year-old mission statement, known as Our Credo, which states that Johnson & Johnson’s “first responsibility is to the patients, doctors and nurses, to mothers and fathers and all others who use our products and services. In meeting their needs everything we do must be of high quality.”

That commitment permeates the decisions that Gorsky makes both inside and outside our company, especially during this coronavirus pandemic.

In this Financial Times profile, read about the decision to make the vaccine available on a not-for-profit basis, his work to help redefine the purpose of corporations through the U.S. Business Roundtable—and his people-first approach to leading at Johnson & Johnson.

Read the article: Johnson & Johnson Chief Looks to the Greater Good

How Johnson & Johnson Is Responding to the COVID-19 Pandemic

Learn about the innovative ways the company is mobilizing to help combat the global outbreak caused by the novel coronavirus.

More from Johnson & Johnson

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.

Meet the medical engineer behind the innovative heart pump that revolutionized cardiac health

Drawing on his fascination with airplane technology, Thorsten Siess, Ph.D., came up with an idea that became the Impella heart pump. Now, 25 years since it entered the market, this groundbreaking device has helped more than 330,000 patients recover from heart injuries.

What you need to know about Johnson & Johnson’s 2024 third quarter earnings

Check out this infographic breakdown of the company’s third quarter performance, with highlights from its Innovative Medicine and MedTech businesses.